Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT03886831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03886831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
February 11, 2019
Completion date
November 16, 2022
Enrollment
232 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, refractory chronic myelomonocytic leukemia, relapsed/refractory acute myeloid leukemia, relapsed/refractory advanced solid tumors, relapsed/refractory diffuse large b-cell lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory myelodysplasia, relapsed/refractory myelofibrosis